Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
albumin (Human) (Plasbumin) (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)
basiliximab (Simulect) (1 trial)
busulfan (Myleran) (1 trial)
cyclophosphamide (cytoxan) (1 trial)
cyclosporine (sandimmune) (1 trial)
fludarabine (fludara) (1 trial)
flumatinib (1 trial)
methotrexate (1 trial)
mycophenolate (CellCept) (1 trial)
rifampin (1 trial)
ruxolitinib (jakafi) (1 trial)
tacrolimus (prograf) (1 trial)
trilaciclib (Cosela) (1 trial)
borneol (1 trial)
neuregulin (1 trial)
pirarubicin (1 trial)
tamoxifen (nolvadex) (1 trial)
toremifene (fareston) (1 trial)
chlorotrianisene (tace) (1 trial)
gemcitabine (gemzar) (1 trial)
genakumab (1 trial)
hs-20089 (1 trial)
irinotecan (Camptosar) (1 trial)
naxitamab (Danyelza) (1 trial)
paclitaxel (taxol) (1 trial)
sargramostim (leukine) (1 trial)
sintilimab (1 trial)
temozolomide (temodar) (1 trial)
tislelizumab (1 trial)
cd19-tricar-silk (1 trial)
cd19-tricar-t (1 trial)
norepinephrine (levophed) (1 trial)
terlipressin (Terlivaz) (1 trial)
beta-Thalassemia (Phase 4)
Breast Neoplasms (Phase 3)
Heart Failure (Phase 3)
Heart Failure, Systolic (Phase 3)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Thalassemia (Phase 4)
Trials (16 total)
Trial APIs (34 total)